FQHC Intel Brief

On Wednesday, September 2, 2026, the President signed H.R. 6500, the “Continuing Appropriations and Extensions Act, 2027,” a short-term continuing resolution providing fiscal year 2027 appropriations to federal agencies through December 11, 2026.

The planning consequence for health centers is the calendar. The sector’s funding risk is no longer one date. It is now two, twenty days apart and both after the November 3 midterms: the CR lapses December 11, and the mandatory Community Health Center Fund expires December 31, 2026.

That places both in the same lame-duck session. THE BILL ITSELF SAYS NOTHING ABOUT HEALTH CENTERS. Across all four divisions of the enrolled text, none of these terms appears: "health center," "section 330," "Community Health Center Fund," "National Health Service Corps," "teaching health center," or "Public Health Service Act."

The divisions are Continuing Appropriations Act 2027; Authorizing Extensions; Surface Transportation Extension Act of 2026; and Department of Veterans Affairs Extenders. Division B extends seventeen authorities running from grain standards to passport fees; the only health provision anywhere in the bill is a Medicare Improvement Fund offset.

What this does do for health centers is on the discretionary side: Division A continues funding under twelve FY2026 appropriations acts including "the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026," available until the first of an enacted FY2027 appropriation or "December 11, 2026."

THE PRACTICAL READ, and it is a clean separation a CFO can plan against: DISCRETIONARY Section 330 keeps flowing at FY2026 levels through December 11, so the September 30 discretionary cliff is deferred rather than cured; the MANDATORY Community Health Center Fund is untouched and still expires December 31. Because the appropriations deadline now lands FIRST, a December omnibus or a second CR is the likeliest vehicle to carry any CHC Fund fix — and Congress has now had one clean opportunity to bridge that gap and used it to trim the Medicare Improvement Fund by $21 million instead.

Health centers have two distinct federal grant-funding clocks. Public Law 119-75 provided $1,858,772,000 in FY2026 annual discretionary funding for primary health care. NACHC asks Congress to increase that amount by $300 million for FY2027, while the House Appropriations Committee's reported H.R.

9260 recommends $1,858,772,000 — flat to FY2026. As of August 26, H.R. 9260 is House-reported, not enacted, and the reported text reviewed contains no Community Health Center Fund extension.

That separate mandatory authority currently provides $4.6 billion for FY2026 plus $1,159,452,055 for October 1 through December 31, 2026. If Congress enacts a continuing resolution, its duration, rate, terms, and anomalies control; do not assume it automatically repeats every FY2026 award term or extends the mandatory fund.

September 30 alone does not prove that a particular center's award balance, staffing, or services stop. Finance leaders should check the center's current H80 Notice of Award, budget and project periods, any revised Notice of Award, enacted text, and current HRSA guidance before changing a forecast.

HRSA placed Notice 2026-15633 on public inspection July 31; official Federal Register publication is scheduled for August 3, and the pilot's effective date is January 1, 2027. Covered-entity commenters asked HRSA to exclude or phase in some entity types.

HRSA declined, reasoning that differences between hospitals and FQHCs do not justify splitting the pilot and that duplicate-discount risk follows selected drugs across every covered-entity type. The notice reports $64.1B in disproportionate-share-hospital purchases (about 79% of total 340B purchases) versus $5.2B for FQHCs and Look-Alikes (about 6%).

DEADLINE BOUNDARY: August 24 is the deadline for eligible manufacturers to submit plans, not a public-comment deadline. Approved plans must pay or deny rebates within 10 calendar days after a completed data submission.

The 15-day grace period applies only to rebate requests for up to two unreplenished accumulated packages dispensed before the pilot's effective date; it is not a general implementation extension. HRSA predicts limited cash-flow harm while acknowledging cited modeling that financing burdens may be disproportionately larger for small entities.

Those are agency positions and modeled estimates, not observed FQHC outcomes. No manufacturer approvals are named. The notice describes commenters generically, so this record does not attribute the exemption request to NACHC.

On July 21, 2026 the U.S. Court of Appeals for the D.C. Circuit upheld a lower court and ruled that Section 340B does not permit manufacturers (Novartis and Johnson & Johnson) to unilaterally replace up-front 340B discounts with a post-purchase rebate model unless the HHS Secretary approves it — holding, in effect, that the statute puts the Secretary and not the manufacturers in control of the program.

The decision preserves the up-front-discount structure that community health centers and their contract pharmacies depend on, while leaving open whether HHS could authorize a rebate model in the future. It is a defensive win, not a permanent fix: other manufacturer proposals and HHS's own rebate-pilot review remain live.

Eli Lilly's June 1 five-day ultimatum escalated on June 18, 2026, when the manufacturer cut off 340B pricing for covered entities that refused to share in-house pharmacy claims data — Lilly directed wholesaler McKesson to end Tampa General Hospital's discounts after it missed the deadline, per the hospital's complaint. Tampa General sued Lilly on July 2 in the U.S. District Court for the Middle District of Florida, alleging the cutoff raised its average costs for Lilly medications 25-50% — losses the complaint pegs at roughly $24.7 million a year, including a 35.9% jump on Mounjaro.

Separately, 72 bipartisan U.S. House members — led by Reps. Doris Matsui (D-CA) and Jack Bergman (R-MI) — signed an early-July letter to HHS Secretary Kennedy and HRSA Administrator Engels urging use of 'any enforcement mechanisms available' against Lilly's move and restoration of 340B pricing.

Coverage so far documents hospitals as the entities cut off; no health-center termination has been confirmed, but FQHCs dispensing Lilly products face the same claims-data condition documented in the June 1 ultimatum item and should confirm their data-sharing posture now.

Federal effectuated-enrollment data posted in late June — analyzed in an ASPE issue brief (June 26) and reported state-by-state by the Associated Press on July 6 — shows about 19.2 million people had ACA Marketplace coverage in February 2026, roughly 2.6 million fewer than in February 2025, following the January 1 expiration of enhanced premium tax credits.

Measured from 2025's 22.1 million peak, KFF puts the decline at 13% and notes average monthly premium payments jumped 58%; KFF projects enrollment could average roughly 17.5 million by the end of 2026. The state picture is stark: Ohio and Oklahoma each lost more than 32% of enrollees; Arizona, South Carolina, Minnesota, Indiana, Michigan, Mississippi, Louisiana, and Missouri each lost more than a quarter; Florida lost the largest raw number (~443,000).

Only New Mexico gained enrollees (+14%) — the one state that fully replaced the lost federal subsidies with its own funds. HHS separately attributes 2.9 million of the enrollment reduction to program-integrity actions (a distinct measure, not the same 2.6M year-over-year figure).

Every Marketplace dropout is a prospective uninsured sliding-fee patient — a durable uncompensated-care pressure signal for FQHCs nationwide through 2026.

Acting U.S. Attorney General Todd Blanche announced (April 7, 2026) the National Fraud Enforcement Division (NFED) — a stand-alone DOJ litigating division consolidating the Tax Section, Health Care Fraud Unit, and Market/Government/Consumer Fraud Unit under one assistant attorney general. Each U.S. Attorney's office must designate a prosecutor to NFED within 21 days.

A new National Fraud Detection Center generates investigative leads from federal financial data — meaning billing anomalies can trigger investigation independent of whistleblower complaints. Combined with FY2025 record $6.8B FCA recoveries (84% from healthcare = $5.7B), 2026 enforcement risk is structurally elevated for FQHCs.

PPS billing, incident-to claims, telehealth FQHC distant-site billing, 340B claim integrity, and Anti-Kickback/Stark exposure are all in scope.

California's enacted FY2026-27 budget provides $250 million for public hospitals and $420 million for benefits-enrollment staffing, but $0 for the mandated indigent-care costs counties must absorb as H.R. 1's Medicaid changes phase in.

The California State Association of Counties (CSAC) had sought $50 million for the fiscal year that began July 1 and $462 million for 2027-28; CSAC CEO Graham Knaus said flatly, 'There is zero in the state budget related to indigent care.' Sonoma County — which in May estimated a three-year, $39.6 million indigent-care cost including its County Medical Services Program (CMSP, the safety net for people who don't qualify for Medi-Cal) — projects per April estimates that its CMSP caseload could balloon from 97 people today to roughly 11,560 as coverage losses hit.

Local clinics have asked the county for $12 million to prepare for the coming wave of uninsured patients; county officials are holding off on committing funds until next year's full H.R. 1 impact is clearer.

DHCS updated its Medi-Cal Eligibility federal-impact page on July 1, giving California FQHC enrollment, eligibility, and navigation teams an official operating map for H.R. 1 implementation.

The page consolidates the narrowed qualified-noncitizen definition starting October 1, 2026; Medicaid work and community-engagement requirements starting January 1, 2027; six-month eligibility checks for adults 19-64; retroactive-coverage limits; duplicate-enrollment data matching; and cost-sharing rules that begin October 1, 2028 while exempting community clinic services.

It also links DHCS' H.R. 1 implementation plan. The federal comment window on CMS' interim final rule closed July 31, 2026; teams should now preserve submitted comments and track CMS and DHCS implementation guidance.

A coalition of 25 states and the District of Columbia, with California among the co-leads, filed Commonwealth of Massachusetts v. Oz, No. 1:26-cv-12962-RGS, on June 29, 2026. The filing challenged CMS-2454-IFC provisions governing the medically-frail exclusion and related verification and hardship rules.

The rule's additional medically-frail criterion asks whether a qualifying condition significantly impairs the ability to comply with community engagement; the complaint disputes that implementation. This filing did not decide the merits, a person's exclusion, or a number of FQHC patients who will lose coverage.

A June 29 Federal Register correction replaces 42 C.F.R. §§ 435.557–435.558. The California filing release also described August 31 as a notification deadline, but § 435.561(b)(1) and CMS Table 2 place initial outreach in September, August, or July according to the state's one-, two-, or three-month applicant lookback.

The responsible state Medicaid agency controls verification, official notice, and eligibility decisions. FQHC teams should use current federal and state instructions, avoid predicting a result, and keep disability, eligibility, work, income, immigration, and clinical records out of FQHC Talent.